Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live
audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review
highlights from its Phase 2 clinical presentations at the 59th American
Society of Hematology (ASH) Annual Meeting and Exposition taking place
December 9-12, 2017 in Atlanta, Georgia.

Participants can access the live conference call by dialing 877-312-5848(domestic)
or 253-237-1155(international) and referring to the
Acceleron ASH 2017 update.

A replay of the webcast will be available approximately two hours after
the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company
dedicated to the discovery, development, and commercialization of
therapeutics to treat serious and rare diseases. The Company's
leadership in the understanding of TGF-beta biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept
planned in pulmonary arterial hypertension.